Primary effusion lymphoma (PEL) is a distinct clinicopathologic entity associated with human herpesvirus 8 (HHV8), which usually presents as a lymphomatous body cavity effusion. Rare cases of PEL are extracavitary and manifest as a solid tumor mass. Here we report an unusual case of extracavitary PEL (EPEL) involving lymph nodes with no evidence of a body cavity effusion. The neoplasm was comprised of large pleomorphic cells with prominent nucleoli and frequent mitotic figures that expressed HHV8, EBV, CD38 and CD30, but lacked all lineagespecific markers. The patient was found to be HIV positive after the diagnosis of EPEL. Antiretroviral therapy initially reduces tumor size, but the patient expired three months later due to multiple complications. PEL and EPEL are differing manifestations of a rare disease entity as defined by the World Health Organization 2008 classification. It is unknown why a small subset of these cases forms extracavitary masses with or without malignant effusions. Comparison with mouse xenograft models may provide unique insights into the pathogenesis of this disease for possible future studies.
Introduction
Primary effusion lymphoma (PEL) is an uncommon aggressive B-cell lymphoma that is universally associated with human herpesvirus-8 (HHV8) [1, 2] . Typically, PEL presents with malignant effusions, without an associated tumor mass [3] . This lymphoma is most frequently diagnosed in HIV-positive patients, but may follow solid organ or stem cell transplantation. Most cases of PEL harbor the Epstein-Barr virus (EBV), which together with HHV8, is postulated to drive malignant transformation. Infrequently, PEL has been reported in the absence of immunosuppression in elderly patients in the Mediterranean where a high prevalence of HHV8 has been documented [4, 5] .
Extracavitary PEL (EPEL) is a rare manifestation of PEL that occurs as an isolated tumor mass. It may be synchronous or metachronous with cavitary effusions, but may also arise independently [6] . EPEL exhibits morphologic and immunophenotypic features as well as expression of specific genes that overlap with classical PEL [7] . The rarity of EPEL however, has hindered progress in understanding its pathogenesis.
We report an unusual case of EPEL involving lymph nodes in a patient with no known immunosuppression at the time of diagnosis. No body cavity effusions or other extranodal sites of disease were detected on staging studies. A workup triggered after the diagnosis confirmed HIV infection. This case raised the following important considerations: (1) the need for a high index of suspicion in the workup of nodal large cell lymphomas with atypical immunophenotypic features; (2) awareness of EPEL as a differential diagnostic consideration in unusual anatomic sites; (3) the need for thorough workup for immunodeficiency even in the absence of clinical history due to its strong association with cases of PEL and EPEL.
Case report
A 49-year old man presented with a rapidly enlarging and painful right neck mass, anorexia and an unintentional 80-pound weight loss over a period of 2-3 months. Apart from bipolar affective disorder, he had no past medical or family history. On physical examination, a 10 cm firm, non-tender, fixed mass without overlying skin changes was present in his right neck which extended from the angle of the jaw to the supraclavicular fossa vertically, to the midline of the neck anteriorly and to the lateral occiput posteriorly. A CT scan revealed a multilocular mass representing a collection of matted lymph nodes. An excisional biopsy was evaluated by histology, flow cytometry, and cytogenetic studies. Systemic workup revealed mild splenomegaly, but no effusions or other nodal or extranodal sites of disease. After an extensive immunohistochemical workup, a diagnosis of EPEL was made. A complex clonal karyotype was obtained by conventional cytogenetic analysis. The co-expression of HHV8 and EBV in neoplastic cells substantiated the diagnosis. Although there was no history of immunosuppression, HIV testing was warranted given the association of EPEL with HIV, which showed that the patient was seropositive for HIV with a high serum viral load and a low CD4 count. He also had marked anemia and neutropenia although a bone marrow biopsy showed no involvement by lymphoma.
Six weeks after the diagnosis of EPEL, the patient was hospitalized for Salmonella bacteremia, and started on highly active antiretroviral therapy (HAART). Two weeks later, the mass slightly diminished in size; he was given localized radiation to the right neck. He was hospitalized again shortly thereafter for worsening shortness of breath and developed bilateral subdural hematomas after sustaining a fall. His mental status continued to deteriorate and the clinical course was further complicated by Salmonella sepsis. The patient was transferred to hospice care and expired two weeks later.
Materials and methods
The case was sent in consultation to the Department of Pathology at Stanford University Medical Center. All investigations were carried out with the approval of the institutional review board of Stanford University.
Immunohistochemistry and in situ hybridization studies were carried out as part of the routine clinical workup of the case. An initial panel of immunohistochemistry was performed at the outside institution and was reviewed: these included CD20, CD3, CD5, CD43, CD10, BCL6, BCL1, BCL2, Ki67, cytokerin, HMB45, Melan A and S100. Additional immunohistochemical stains, including CD30, CD38, CD79a, OCT2, CD138, CKMIX, EMA, HHV8, MUM1, CD56, CD45RB and SALL4, and EBV/EBER in situ hybridization, were performed on an automated immunostainer (Ventana Benchmark, Roche/Ventana Medical Systems, Tucson, AZ). A 4-color Fluorescence-Activated Cell Sorter-Calibur instrument and Cell Quest software (Becton-Dickinson, San Jose, CA) was used. Specific cell populations were identified and gated based on antigen expression patterns compared by fluorescence intensity against standard isotype controls.
Results
Histologic examination revealed remnants of a lymph node capsule with complete architectural effacement by an abnormal infiltrate composed of sheets of large cells. Scant numbers of small lymphocytes and histiocytes were scattered in the background. The atypical large cells were dishesive and had highly pleomorphic nuclear outlines with one to several prominent nucleoli, vesicular chromatin and moderate amounts of cytoplasm. Atypical mitotic figures were frequent. The histologic differential diagnosis included epithelial, melanocytic and hematolymphoid malignancy ( Fig. 1) .
A broad immunohistochemical panel was performed and the atypical cells lacked cytokeratins (AE1, CAM5.2, and CK5/6), melanocytic markers (S100, Melan-A and HMB-45), and several hematologic markers (CD45, CD43, CD20, CD79a, CD138, PAX5, OCT2, CD3, CD5, CD56, BCL1, BCL2, CD10, and BCL6). Diffuse and strong expressions for CD30, CD38, and MUM1/ IRF4 were detected ( Fig. 1 and Table 1 ). A stain for the proliferation marker, Ki67, showed a high growth fraction of 90%. Additionally, HHV8 and EBV/EBER showed strong expression in the majority of atypical cells.
Flow cytometric analysis showed an increased proportion of CD8 + T-cells, with an inverted CD4/CD8 ratio, although no aberrant loss of T-cell antigen expression was noted. In addition, no light chain-restricted B-cell population was identified. Cytogenetic studies demon-strated a complex clonal karyotype: 43, X, − Y, del (1) t(1;16) (p13; q11.2), add (2) (p23), add (5) (p11.2), − 6, del (7)(p13), add (8) (p22), del (9) (q21.2q22), del (10) (p11.2p13), − 16, − 18, add (22) (q11.2), + mar[CP10]/46, XY [1] (Fig. 2) .
Discussion
The histologic differential diagnosis of a dishesive large cell neoplasm completely effacing the normal nodal architecture is broad and requires correlation with patient history and immunophenotype for accurate diagnosis. The morphologic differential diagnosis included metastatic carcinoma and melanoma in addition to large cell lymphomas. The patient had no prior history of malignancy nor a documented history of immunodeficiency at the time of consultation. The most common nodal large PEL typically grows in body cavities as a malignant effusion and shares some morphologic overlap with both the immunoblastic variant of diffuse large B-cell lymphoma and anaplastic large cell lymphoma, including large cells with polyploid and lobated nuclei, prominent nucleoli, and abundant amphophilic cytoplasm or plasmacytoid features. The spectrum of PEL has been expanded by the identification of rare extracavitary forms of lymphoma without a malignant effusion. The neoplastic cells of solid EPEL show a similar morphologic appearance to those of PEL or plasmablastic lymphoma [8, 9] .
The immunophenotype of PEL/EPEL is strikingly nonspecific, with neoplastic cells typically expressing common leukocyte antigen (CD45) in the absence of most B-lineage antigens, including CD20, CD19, CD79a, as well as surface and cytoplasmic immunoglobulins (Ig). B-cell origin can be demonstrated by the presence of a clonal IG gene rearrangement [10] . Most PELs show somatic hypermutation of the IG variable region genes as well as frequent somatic hypermutation of the BCL6 gene, although BCL6 protein is generally absent. The lack of B-cell antigens may reflect post-germinal center differentiation, as evidenced by the expression of activation/ plasma cell-related markers. A variety of nonlineage-specific antigens, including CD30, CD38, CD138, and epithelial membrane antigen (EMA) may be expressed [11] . Gene expression profiling studies of PEL from HIV patients revealed similarity to immunoblasts from EBV + lymphoblastoid cell lines and AIDS-associated immunoblastic lymphoma, and to plasma cells from plasma cell myeloma cell lines [12, 13] . Unlike plasmablastic lymphoma, they are usually positive for both EBV and HHV8, although EBV-negative cases have also been reported [14] . No rearrangements involving MYC, BCL2, BCL1, or BCL6 were found. PEL generally lacks T-cell markers, although aberrant expression of T-cell markers can occasionally occur [15] .
EPEL is extremely rare with only a small number of reported cases. It has been reported in the gastrointestinal tract and other extranodal sites, including the lungs, central nervous system, and skin [9] . It can also occur as a nodal extracavitary lymphoma, as in the current case [9, 16] . Although EPEL develops primarily, although not exclusively, in patients with AIDS or severe immunodeficiency [2, 8] , the diagnosis of EPEL warranted HIV testing, which was positive in this case. PEL has an extremely unfavorable prognosis with a median overall survival time of less than six months [17] . The lack of institution of HAART therapy before developing PEL is the strongest predictor of poor outcome in HIV-patients with PEL [4, 18] , as seen in the current case. Inhibition of HIV viral replication can slow the progression of PEL [4] , and indeed, in our case, the tumor showed a slight clinical regression after two weeks of antiretroviral therapy. Patients who develop PEL may be more immunocompromised than patients with EPEL as reported in one study where eight HIV-positive patients with EPEL had a slightly more favorable outcome when compared with 21 patients with classical PEL [11] .
Given the rarity of PEL, its pathogenesis is informed by case reports or small case series as well as from xenograft models similar to those we have previously characterized [19] . The tumor cells in the mouse model demonstrated similar morphologic and immunophenotypic features to the current case, including positivity for HHV8, EBER, CD30 and CD138 while lacking B-cell markers. Of note, prominent solid tumor nodules were identified on the intestinal serosal surfaces in the mouse model [19] , which Negative S100 Negative SALL4 Negative was previously described in an HIV-positive patient with PEL (including lymphomatous effusions) and secondary intestinal involvement leading to bowel obstruction [18] . Another HIV patient with PEL showed a distinctive multinodular pattern of disease involving the pleural surfaces in addition to the characteristic malignant effusions [20] , further underscoring the highly unusual disease distribution patterns found in patients with PEL. The predilection exhibited by PEL for body cavities may be related to the cellular milieu of the mesothelial lining cells. Overproduction of cytokines, particularly, interleukin 6 and 10 by mesothelial cells provides a conducive microenvironment that facilitates the proliferation of late developmental stages of the neoplastic B cells of PEL [21] . Furthermore, this propensity could be the result of a unique homing pattern induced by HHV8 infection [22] . The serous membrane growth pattern may also be related to cell adhesion mechanisms, for example, the expression of CD138 may cause enhanced adherence to extracellular matrix components [23] . Interestingly, the current case did not express CD138, which may be directly related to why this patient did not have lymphomatous effusions in body cavities. Although the majority of PEL/ EPEL cases show lymphomatous effusions, what causes the formation of discrete nodules or masses, whether the presentation is nodal or extranodal, and whether there are tumor masses associated with the tissues lining the body cavities, is currently unknown. Alterations in homing receptors and cell adhesion molecules are likely responsible for these differences and warrant further investigation, in patient samples as well as in mouse models, to elucidate the mechanisms involved in body cavity distribution of lymphomatous effusions as well as the less common cases showing tumor mass formation.
